FIS
90
12
APA
32
-2
MSFT
58
3
CAG
39
2
MRK
50
2
ADP
69
3
NRG
64
2
KO
67
2
FSLR
44
-2
ESS
39
-5
HBAN
76
2
GLW
53
3
FRT
53
-2
CPB
25
3
DG
27
2
DUK
60
5
ETR
65
-3
FITB
73
15
NWSA
76
3
DGX
53
3
FIS
90
12
APA
32
-2
MSFT
58
3
CAG
39
2
MRK
50
2
ADP
69
3
NRG
64
2
KO
67
2
FSLR
44
-2
ESS
39
-5
HBAN
76
2
GLW
53
3
FRT
53
-2
CPB
25
3
DG
27
2
DUK
60
5
ETR
65
-3
FITB
73
15
NWSA
76
3
DGX
53
3
Financhill
Back

Pacira BioSciences 10K Form

Sell
39

PCRX
Pacira BioSciences

Last Price:
$26.75
Seasonality Move:
4%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive PCRX News And Ratings

See the #1 stock for the next 7 days that we like better than PCRX

PCRX Financial Statistics

Sales & Book Value

Annual Sales: $701M
Cash Flow: $31M
Price / Cash Flow: 7.37
Annual Sales: $16.83
Price / Book: 1.61

Profitability

EPS (TTM): -2.19000
Net Income (TTM): $-99.6M
Gross Margin: $530.5M
Return on Equity: -11.94%
Return on Assets: -6.32%

Pacira BioSciences Earnings Forecast

Key Pacira BioSciences Financial Ratios

  • The Gross Profit Margin over the past 17 years for PCRX is 75.69%.
  • The Selling, General & Administrative Expenses for PCRX have been equal to 41.96% of Gross Profit Margin.
  • The Research & Development expenses have been 11.64% of Revenue.
  • The Net Earning history of PCRX is -14.20% of Total Revenues.
  • Per Share Earnings over the last 17 years have been positive in 8 years.

Pacira BioSciences Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: PCRX
CUSIP: 695127
Website: pacira.com

Debt

Debt-to-Equity Ratio: 0.75
Current Ratio: 2.4
Quick Ratio: 1.93

Price-to-Earnings

Trailing P/E Ratio: 28.52
Forward P/E Ratio: 7.41

PCRX Technical Analysis vs Fundamental Analysis

Sell
39
Pacira BioSciences (PCRX) is a Sell

Is Pacira BioSciences a Buy or a Sell?